Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus to Provide Third Quarter 2026 Financial Report and Development Update

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. will release its third quarter 2026 financial results on November 5, 2026. The report will detail the company's progress with botensilimab and balstilimab, particularly in relation to the Phase 3 neoadjuvant ROBBIN trial for earlier-stage colon cancer. This update aims to strengthen the clinical and regulatory foundation for these therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus is advancing botensilimab and balstilimab.
  • The company is preparing for a Phase 3 trial.
  • Focus on earlier-stage colon cancer shows potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
5.5%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Balstilimab
Phase 3 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus’ recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for

Frequently Asked Questions

When will Agenus release its Q3 2026 financial results?

Agenus will release its Q3 2026 financial results on November 5, 2026.

What therapies are being advanced by Agenus?

Agenus is advancing botensilimab and balstilimab.

What is the focus of the Phase 3 ROBBIN trial?

The Phase 3 ROBBIN trial focuses on earlier-stage colon cancer.

What is the purpose of the upcoming earnings release?

The earnings release will review Agenus' recent progress and developments.

ShareAdd on Google
Tags: AGEN Agenus botensilimab balstilimab Phase 3 trial colon cancer
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BalstilimabPhase 3
Colorectal Cancer →

Catalyst track record

+203%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →